OncoResponse raises $150M total, closes $6M Series D in April 2025; backed by ARE, Rice University, Takeda

OncoResponse, headquartered in Seattle, has raised $150M total with a recorded $6M Series D round in April 2025 and is backed by investors including ARE, Rice University, and Takeda Pharmaceuticals.

No comments yet.